A subscription model can make repeat prescriptions look automatic from the outside: order once, then everything after that is a tap and a short wait. Underneath, a private prescriber still has to decide the medicine remains appropriate every time it's reissued. Getting that review cycle right, proportionate for the patient and robust enough for safety, is one of the less visible but more consequential parts of running a telehealth service.
NHS repeat dispensing is not the same as a private refill
The NHS Electronic Prescription Service supports genuine repeat dispensing: a GP authorises a batch prescription with a fixed number of issues, valid for up to 12 months, and the patient collects each instalment without a fresh consultation. Private electronic prescriptions in telehealth do not work this way.
A private prescriber issues one prescription at a time. There is no NHS-style batch authorisation sitting behind it, so every "repeat" a patient orders is, legally, a new prescribing decision that has to be made again, not simply released from a pre-approved schedule.
Why every reissue needs a fresh clinical decision
Prescribing standards from the GPhC, GMC and NMC all say the same thing in different words: a prescriber is accountable for every prescription they sign, and that accountability does not lessen because the patient has ordered the same medicine before. Continuing a treatment is still a clinical decision, not an administrative one.
That matters operationally. A platform that lets a refill go through on payment alone, without any prescriber input since the first order, is asking the prescriber to defend a decision they did not actually make at the point it mattered.
Building a review cadence into the platform
Most operators solve this by attaching an expiry to the clinical authorisation, not just the prescription itself. A typical pattern: the first order carries a full consultation, refills are allowed for a set number of cycles, then a lightweight review is required before the next one is released.
The review interval should track clinical risk, not convenience. A stable, long-established repeat might reasonably carry a longer interval than one still being titrated, and the prescriber, not a default setting, should be the one confirming that gap is appropriate for the individual patient.
- Set the cadence per medicine category, not one blanket interval for the whole catalogue
- Flag the review as due a few days before it blocks checkout, so refills don't stall unexpectedly
- Log every review decision against the prescription, not just against the patient record
- Route anything outside the standard pattern, such as missed doses or new symptoms, to a prescriber, not a script
A repeat prescription is a new clinical decision every time it's reissued, not a renewal of the first one. Billing and clinical review are two different clocks, and conflating them is how a lapsed review turns into a prescription nobody actually re-authorised.
What a repeat review actually needs to capture
A repeat review does not need to replicate the first consultation. It needs enough to confirm the original decision still holds: is the patient taking it as prescribed, have they had side effects, has anything changed that would alter the risk picture, and are there safety-netting questions specific to that medicine class.
Keep the questionnaire short enough that patients actually complete it honestly. A review that takes ten minutes to fill in gets rushed or abandoned; one that takes ninety seconds and asks the right three or four questions gets a truthful answer.
Handling lapses, gaps, and stockpiling
Patients do not order to a tidy schedule. Some lapse for months and come back expecting an instant refill; others try to order early, sometimes because they have genuinely run out sooner, sometimes because they are building a stockpile. Both need a rule, not a judgement made fresh each time by whoever happens to be on shift.
A sensible default treats a long gap as reason to re-open a fuller review rather than waving it through as a routine repeat, and treats an early reorder request as a prompt for the prescriber to ask why, before assuming it is fine. Keeping a clear record of what was asked and answered at each point makes both calls defensible later.
A refill button is a convenience feature. The clinical decision behind it still has to be made, in full, every single time.
Where automation helps, and where it can't
Reminders, expiry flags, questionnaire routing and stock checks are all fair game for automation, and getting them right is most of what makes a repeat-prescription process feel effortless to the patient while staying safe underneath. None of that is the clinical decision itself.
The line to hold is that software can decide when a review is due and what questions to ask; it should not be deciding, on its own, whether the answers are good enough to reissue. That judgement stays with the prescriber, every time, however routine the case looks.
How PExpo supports repeat-prescription operations
PExpo's dispensing layer sits underneath the clinical decision, not in place of it: once a prescriber confirms a repeat, the order flows straight to dispensing and fulfilment without the patient re-entering details or the clinic chasing a separate system. Review gating, expiry logic and audit trails sit alongside the checkout flow rather than bolted on after it.
For clinics running a subscription-style repeat model, that means the commercial cadence of billing and renewal and the clinical cadence of review and reissue can be configured separately, so a lapsed clinical review blocks dispensing even if the subscription itself is still active.
Repeat prescriptions are where a large share of day-to-day volume in UK telehealth actually sits, and where the safety margin gets tested hardest, because familiarity breeds shortcuts. A review cadence that is proportionate to risk, backed by a clear audit trail, and enforced in the platform rather than left to goodwill, is what keeps that volume safe. See our guides to electronic prescriptions in private telehealth and patient retention for how the pieces around it fit together.
Frequently asked questions
Can a UK telehealth patient get a repeat prescription without seeing a prescriber again?
No, not in the NHS repeat-dispensing sense. A private prescriber still has to review and reissue each prescription. What varies is how light that review is, not whether it happens at all.
How often should a repeat prescription review happen?
It depends on the medicine and the individual patient's risk profile, so there is no single correct interval. Stable, well-established repeats can often carry a longer gap between reviews than medicines still being titrated or monitored closely, and the prescriber should be the one setting that interval, not a fixed platform default.
What happens if a patient misses their repeat prescription review window?
Good practice treats a missed window as a reason to re-open a fuller review rather than releasing the medicine automatically once the patient re-engages. How that is handled should be documented in the clinic's SOPs so the decision is consistent, not made ad hoc each time.
